Company KaloBios Pharmaceuticals Inc Nasdaq
Equities
US48344T1007
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
04-12 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
03-08 | Final DIP Financing Approved for Humanigen, Inc. | CI |
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 4 | 100.0 % | 3 | 100.0 % | -30.07% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 4 | 100.0 % | 3 | 100.0 % | -30.07% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 06/01/16 |
Omar Ahmed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 05/07/20 |
Bob Atwill
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 06/01/16 |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 05/07/20 |
Ronald Barliant
BRD | Director/Board Member | 78 | 06/01/16 |
Rainer Boehm
BRD | Director/Board Member | 63 | 11/02/18 |
Omar Ahmed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 119,080,135 | 106,754,128 ( 89.65 %) | 0 | 89.65 % |
Company contact information
Humanigen, Inc.
830 Morris Turnpike 4th floor
07078, Essex County
+973 200 3100
http://www.humanigen.comSector
1st Jan change | Capi. | |
---|---|---|
-3.79% | 87.06B | |
+1.45% | 40.25B | |
-15.94% | 31.09B | |
+52.66% | 24.74B | |
-14.50% | 15.91B | |
-9.12% | 11.96B | |
-14.38% | 11.92B | |
-42.56% | 11.61B | |
+4.87% | 8.73B |
- Stock Market
- Equities
- HGEN.Q Stock
- Stock
- Company KaloBios Pharmaceuticals Inc